Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790034 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
A Phase 2 study, sponsored by Newron Pharmaceuticals SPA.
- Terminated
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT02790034 is a Phase 2 study that was terminated before completion, run by Newron Pharmaceuticals SPA. The registered enrollment target is 129 participants.
The verdict
NCT02790034, a Phase 2 study, was terminated before completion, sponsored by Newron Pharmaceuticals SPA.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing respiratory abnormalities in Rett Syndrome in an initial double blind 24 week period followed by an open label treatment phase of up to 168 weeks (the latter for patients with no safety and tolerability issues).
Interventions
- DRUG Placebo
- DRUG Sarizotan low dose
- DRUG Sarizotan high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2016-10-26 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02790034
The ClinicalTrials.gov registry entry for NCT02790034 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Newron Pharmaceuticals SPA, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02790034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02790034 about?
NCT02790034 is a clinical study titled "Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms". This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing respiratory abnormalities in Rett Syndrome in an initial double blind 24 week period followed by an open label treatment phase of up to 168 weeks (the latter for patients with no safety and tolerability issues).
What is the current status of trial NCT02790034?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2016-10-26. Estimated completion is 2020-05-04.
What interventions are being tested in trial NCT02790034?
The interventions under investigation include: Placebo (DRUG), Sarizotan low dose (DRUG), Sarizotan high dose (DRUG).
Who is sponsoring clinical trial NCT02790034?
This trial is sponsored by Newron Pharmaceuticals SPA, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.